🇺🇸 FDA
Patent

US 8829024

Combination steroid and glucocorticoid receptor antagonist therapy

granted A61KA61K31/437A61K31/573

Quick answer

US patent 8829024 (Combination steroid and glucocorticoid receptor antagonist therapy) held by Corcept Therapeutics Incorporated expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/437, A61K31/573, A61K45/06, A61P